| Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment. | |
| | |
MedLine Citation:
|
PMID: 10780315 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM OF THE STUDY: We studied the effects of fluvastatin and bezafibrate in monotherapy and in combination on plasma fibrinogen, t-plasminogen activator inhibitor (PAI-1) and C reactive protein (CRP) in patients with coronary artery disease (CAD) and mixed hyperlipidaemia. DESIGN: In this randomised, double blind, multicentre trial 333 patients with stable angina pectoris or previous myocardial infarction or coronary revascularisation and mixed hyperlipidaemia (LDL-cholesterol 135-250 mg/dl and triglycerides (TG) 180-400 mg/dl) were randomised to fluvastatin 40 mg, bezafibrate 400 mg, fluvastatin 20 mg + bezafibrate 400 mg or fluvastatin 40 mg + bezafibrate 400 mg treatments for 24 weeks. RESULTS: Plasma fibrinogen significantly decreased after treatment with the combinations fluvastatin+bezafibrate (-14 and -16%) and with bezafibrate monotherapy (-9%). No significant reduction was observed after fluvastatin monotherapy (-4%). No significant changes were observed in PAI-1 and CRP plasma levels. Combination therapy significantly decreased both LDL-C and TG, and significantly increased HDL-C. CONCLUSIONS: The combined effects on fibrinogen and plasma lipids achieved by fluvastatin and bezafibrate combination treatment might be more useful than the simple reduction of cholesterol in preventing ischaemic cardiovascular disease. |
| | |
Authors:
|
M Cortellaro; E Cofrancesco; C Boschetti; F Cortellaro; M Mancini; M Mariani; R Paoletti |
Related Documents
:
|
3145745 - Effects of cs-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a (... 17520105 - Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia. 11930385 - Hypercholesterolemia: a look at low-cost treatment and treatment adherence. 18418005 - Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chro... 19944395 - Challenging the dogma of high target doses in the treatment of heart failure: is more a... 7015795 - Captopril, an orally active converting enzyme inhibitor, in the treatment of primary hy... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: Thrombosis and haemostasis Volume: 83 ISSN: 0340-6245 ISO Abbreviation: Thromb. Haemost. Publication Date: 2000 Apr |
Date Detail:
|
Created Date: 2000-07-31 Completed Date: 2000-07-31 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7608063 Medline TA: Thromb Haemost Country: GERMANY |
Other Details:
|
Languages: eng Pagination: 549-53 Citation Subset: IM |
Affiliation:
|
University of Milan, Italy. centrorc@mailserver.unimi.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antilipemic Agents / administration & dosage*, therapeutic use Bezafibrate / administration & dosage*, therapeutic use C-Reactive Protein / analysis* Cholesterol, LDL / blood Coronary Disease / blood* Double-Blind Method Drug Synergism Drug Therapy, Combination Fatty Acids, Monounsaturated / administration & dosage*, therapeutic use Female Fibrinogen / analysis* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*, therapeutic use Hyperlipidemia, Familial Combined / blood, drug therapy* Hyperlipoproteinemia Type II / blood, drug therapy Hypertriglyceridemia / blood, drug therapy Indoles / administration & dosage*, therapeutic use Male Middle Aged Tissue Plasminogen Activator / blood* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Cholesterol, LDL; 0/Fatty Acids, Monounsaturated; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Indoles; 41859-67-0/Bezafibrate; 9001-32-5/Fibrinogen; 9007-41-4/C-Reactive Protein; 93957-54-1/fluvastatin; EC 3.4.21.68/Tissue Plasminogen Activator |
| Comments/Corrections | |
Comment In:
|
Thromb Haemost. 2001 Jan;85(1):189-90
[PMID:
11204580
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese indi...
Next Document: Intermediate and severe hyperhomocysteinemia with thrombosis: a study of genetic determinants.